The scale of BioNTech’s post-COVID reinvention is on full display this week in Chicago. At the American Society of Clinical Oncology (ASCO) Annual Meeting, running through June 2, the Mainz-based biotech is unveiling what it calls its most extensive data release yet — more than 25 Phase 2 and Phase 3 studies across multiple tumour types, including 13 pivotal trials. The push comes as the company balances a massive cash war chest with deep cost cuts and a planned $1 billion share buyback.
ADC Trio Takes Centre Stage
Three antibody-drug conjugates (ADCs) are stepping into the spotlight for the first time together. Trastuzumab Pamirtecan, a HER2-directed ADC, posted a confirmed objective response rate of 47.9% in a Phase 2 cohort of 145 patients with HER2-positive advanced endometrial cancer. Median progression-free survival reached 8.1 months. The candidate already carries both FDA Fast Track and Breakthrough Therapy designations from 2023. BioNTech and its partner DualityBio aim to submit a Biologics License Application to the FDA in 2026, subject to regulatory feedback; Chinese authorities have already accepted a corresponding filing for review. The HER2 agent now enters a Phase 3 head-to-head trial against chemotherapy in pretreated, HER2-expressing recurrent endometrial cancer.
Two other ADCs are making progress. BNT326/YL202 (HER3-ADC) is being evaluated in a Phase 1b/2 poster session as a monotherapy and in combination with the immunomodulator Pumitamig in advanced solid tumours. BNT324/DB-1311 (B7H3-ADC) is under a Phase 1/2a study, with a planned Phase 3 trial in metastatic castration-resistant prostate cancer slated for 2026. The multi-target ADC strategy positions BioNTech in a class that has gained significant momentum across the oncology industry.
Pumitamig Adds Another Consistent Dataset
Pumitamig, BioNTech’s lead bispecific antibody, delivered its third consistent global dataset in a midday oral presentation. An interim analysis from the dose-optimisation portion of the Phase 2/3 ROSETTA Lung-02 study showed encouraging anti-tumour activity in first-line non-small cell lung cancer (NSCLC), both squamous and non-squamous, across all PD-L1 expression levels in patients without actionable genomic alterations. The results follow previously reported activity in small cell lung cancer and triple-negative breast cancer. The data feed into an ongoing pivotal Phase 3 trial that directly compares Pumitamig plus chemotherapy against the established first-line NSCLC standard, Merck’s Keytruda (pembrolizumab) plus chemotherapy.
Gotistobart Shows Survival Benefit in Ovarian Cancer
Data from the Phase 2 PRESERVE-004 trial of Gotistobart, a PD-L1/VEGF-A bispecific antibody, demonstrated durable anti-tumour activity and clinically meaningful overall survival in heavily pretreated patients with platinum-resistant ovarian cancer. Given in combination with pembrolizumab, the safety profile was manageable. The findings support Gotistobart’s potential as a chemotherapy-free treatment option in a difficult-to-treat population.
Should investors sell immediately? Or is it worth buying BioNTech?
Financial Strength Meets Operational Overhaul
BioNTech reported €118.1 million in revenue for the first quarter of 2026, alongside a net loss of €531.9 million as oncology and ADC investments ramp up. Cash, cash equivalents and securities stood at €16.8 billion ($19.6 billion) as of March 31. The company reaffirmed its 2026 revenue guidance of $2.3 billion to $2.6 billion. A $1 billion share buyback programme over 12 months is already underway.
Yet the spending is being offset by an aggressive restructuring. Around 1,860 positions are being eliminated, with production sites in Idar-Oberstein, Marburg, Singapore and at partner CureVac closing or downsizing. Management expects annual savings of nearly $585 million by 2029, freeing capital to fund oncology commercialisation.
Analyst Support Holds Despite Stock Slump
The stock traded near €83, roughly 18–20% below its 52-week high of €101.90. A consensus of 19 analysts gives BioNTech a “Buy” rating with an average price target of $123.47. Canaccord Genuity reiterated its buy recommendation on May 28, having trimmed its target from $171 to $158 on May 6. Wells Fargo followed with a buy confirmation on May 22. The contrasting analyst optimism against the net loss and transition costs underscores the market’s focus on pipeline potential.
Pipeline Expansion Sets Up 2026 Milestones
BioNTech now expects 15 active Phase 3 studies by year-end, with seven late-stage oncology data readouts anticipated during 2026 — including the Trastuzumab Pamirtecan BLA submission. Five new pivotal trials for Pumitamig recently launched in triple-negative breast cancer, MSS colorectal, gastric and two NSCLC settings. For a company that has yet to generate any regulatory approval or commercial revenue from its oncology pipeline, the ASCO week represents the most concentrated near-term test of whether its multi-platform strategy can deliver clinical proof-of-concept across multiple tumour types.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from May 29 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 29.
BioNTech: Buy or sell? Read more here...
